Skip to main content
Clinical Trials/NCT00482209
NCT00482209
Completed
Not Applicable

Study of 400mcg Versus 800mcg Buccal Misoprostol Following Mifepristone 200mg for Abortion up to 63 Days Gestation

Gynuity Health Projects4 sites in 2 countries1,220 target enrollmentMay 2007

Overview

Phase
Not Applicable
Intervention
mifepristone, misoprostol
Conditions
Induced Abortion
Sponsor
Gynuity Health Projects
Enrollment
1220
Locations
4
Primary Endpoint
Need for surgical completion for ongoing viable pregnancies at follow up visit (Study day 12-15) or for incomplete abortion at extended follow up visit (Study day (19-22).
Status
Completed
Last Updated
16 years ago

Overview

Brief Summary

This double-blind, randomized study will compare the efficacy and acceptability of mifepristone 200mg followed in 36-48 hours by 400mcg or 800mcg of buccal misoprostol (i.e., in the cheeks) for termination of pregnancy in women up to 63 days LMP.

Detailed Description

The goal of this study is to provide answers to the following four questions: 1. Is a regimen of medical abortion with mifepristone using 400mcg buccal misoprostol as effective and acceptable as using 800mcg buccal misoprostol up to 63 days since the last menstrual period (LMP)? 2. Are the side effects with buccal use tolerable for women? 3. Is buccal administration of misoprostol acceptable to women? 4. When given a choice, do women prefer to take misoprostol at home or in the clinic?

Registry
clinicaltrials.gov
Start Date
May 2007
End Date
October 2009
Last Updated
16 years ago
Study Type
Interventional
Study Design
Parallel
Sex
Female

Investigators

Sponsor
Gynuity Health Projects

Eligibility Criteria

Inclusion Criteria

  • Women 18 years or over presenting for abortion services who consent to participate
  • good general health
  • assessed by a clinician to have an intrauterine pregnancy less than 64 days LMP on Study Day 1 and to be eligible for medical abortion
  • Have ready access to a telephone and emergency transportation;
  • Be willing to provide an address and/or telephone number for purposes of follow-up

Exclusion Criteria

  • Conditions which contraindicate the use of mifepristone or misoprostol
  • Women presenting for medical abortion who do not consent to participate

Arms & Interventions

1

200mg mifepristone followed by 400mcg misoprostol

Intervention: mifepristone, misoprostol

2

200mg mifepristone followed by 800mcg misoprostol

Intervention: mifepristone, misoprostol

Outcomes

Primary Outcomes

Need for surgical completion for ongoing viable pregnancies at follow up visit (Study day 12-15) or for incomplete abortion at extended follow up visit (Study day (19-22).

Time Frame: Study day 12-15 for ongoing viable pregnancies or Study day 19-22 for incomplete abortion at extended follow up visit

Secondary Outcomes

  • Side-effects, acceptability for women(side effects and acceptability recorded at exit interview)

Study Sites (4)

Loading locations...

Similar Trials